Gluten Threshold Study - Wesley Research Institute
Wesley Research Institute

This study aims to determine if there is a minimum threshold or a ‘safe dose’ for the amount of gluten ingested by patients with coeliac disease.

Research Objectives





Estimated completion

June 2024

Total participants required


Study location

The Wesley Hospital

Study type

Investigator Initiated

Patient group

Patients with positive Coeliac Disease biopsy

About this clinical trial

Patients with coeliac disease can experience acute food poisoning symptoms related to an immune activation phenomenon within two hours after ingesting just 5-10 grams of wheat gluten. 

Currently in Australia and New Zealand, the uncertainty over the safe dose of gluten has led to a ‘no detectable’ gluten standard for food labelled ‘gluten free’. However, throughout the rest of the world the ‘gluten free’ standard is 20 parts per million (which is higher than ‘no detectable’). 

Currently, we do not know the minimum dose of gluten that activates an immune response, injures the gut and causes symptoms. This has in turn taken a toll on food safety standards in Australia and worldwide. 

 Dr James Daveson is addressing this knowledge gap through the Gluten Threshold Study. This study will compare small doses of gluten; Each participant is allocated either a dose of gluten or a placebo (which contains no gluten at all) through a process known as randomisation.  The dose of gluten/placebo will be administered in a “gluten challenge”, which means that participants will ingest the gluten/placebo and then be observed for side effects. 

This study aims to determine if there is a minimum threshold or a ‘safe dose’ for the amount of gluten ingested by coeliac disease patients. Other potential outcomes of this study include: 

  • Non-invasive diagnostic test could be developed for ‘at-risk’ relatives 
  • Improved symptom changes for patients 
  • Identify biomarkers for coeliac disease onset 




The impacts of this study are aimed at reducing gluten induced intestinal injury, by understanding the amount of gluten that will induce an immune response. Our results so far have conclusively shown a requirement for updating FDA and EPA regulations around “GF” labelling and further results will enhance and strengthen programs being developed for the advancement of greater food security for the coeliac community. To hear more about these results, please register your interest using the form below.  



This clinical trial has been split into 4 cohorts: 

Cohort 1: 6 patients of high-dose gluten challenge, was completed in November 2022
Cohort 2: 15 patients administered with decreasing amounts of gluten as per the Fibonacci scaling, was completed in May 2023.
Cohort 3: 15 patients administered with decreasing amounts of gluten as per the Fibonacci scaling lower than that of Cohort 2, was completed in November 2023.
Cohort 4: Recruitment for a total of 15 participants is currently open for this cohort and we will be administering doses lower than the minimum established by the FDA and EPA. We expect to begin dosing new participants in February 2024 with completion of study in May 2024.  


Do you meet the following criteria?

  1. Adults 25 to 75 years of age (inclusive)
  2. A history of coeliac disease diagnosed on the basis of duodenal biopsy showing villous atrophy and abnormal coeliac disease-specific serology.
  3. Initiated gluten-free diet at least 2 years prior to screening.
  4. Are based within the Greater Brisbane region

Additional information

You can find out more about the Gluten Threshold Study by visiting the ANZCTR website or by contacting us below.

Lead investigator

  • Dr James Daveson

Clinical trial coordinator

  • Emma Brownrigg

Technical title

A Double-Blind, Placebo-Controlled, Adaptive Dose-Response Study To Assess the Acute Effects of Gluten in Adults with Treated Coeliac Disease.

This clinical trial is now closed for recruitment

If you would like more information about this trial, please complete the contact form below.

Do you consent to be contacted about any current Coeliac Disease research projects?(Required)
I consent to receive updates on Wesley Research Institute news and events, clinical trials, research projects and how to support WRI.
By submitting this form you consent for us to hold your information in accordance with our Privacy Policy
This field is for validation purposes and should be left unchanged.
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram